Clinical, cosmetic and investigational dermatology · 2026
Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen ZeHui, Tang YiYan, Zheng MeiLian, Lin JieChao, Xu JiaBo, Zhang CuiMei, You CaiLian, Wu JinHong, Cao Ning
Аннотация
PURPOSE: To preliminarily evaluate a thermoresponsive hydroxybutyl chitosan (HBC)-assisted topical carteolol delivery regimen combined with pulsed dye laser (PDL), compared with conventional carteolol wet-compress therapy combined with PDL, in infants with superficial infantile hemangiomas.
PATIENTS AND METHODS: This single-center, open-label, randomized exploratory study included 40 infants with superficial IHs, who were assigned to an HBC group or a control group at a 1:1 ratio. Both groups received PDL. The HBC group received immediate post-laser topical application of the optimized HBC-carteolol mixture, whereas the control group received conventional topical carteolol wet-compress therapy after PDL. The predefined efficacy assessment was performed at the 6-month visit, while clinical follow-up continued for 6 to 12 months as routine clinical follow-up. The primary endpoint was the number of PDL treatment sessions completed during the 6-month treatment period. Secondary outcomes included 6-month Hemangioma Activity Score (HAS), change in HAS from baseline to 6 months, and treatment-related complications.
RESULTS: At the predefined 6-month assessment, the HBC group required fewer treatment sessions than the control group during the 6-month treatment period (3.5 ± 0.6 vs 4.7 ± 0.7, P < 0.001). The 6-month HAS was numerically lower in the HBC group than in the control group, but the difference was not statistically significant (0.3 ± 0.4 vs 0.4 ± 0.4, P = 0.272). The HAS change score also did not differ significantly between groups (4.6 ± 0.5 vs 4.5 ± 0.5, P = 0.440). The aggregate treatment-related local complication rate was lower in the HBC group than in the control group (5.0% vs 35.0%, P = 0.048).
CONCLUSION: In this single-center exploratory randomized study, the HBC-carteolol-PDL regimen was associated with fewer treatment sessions and complications than conventional carteolol wet-compress therapy combined with PDL. Further component-controlled studies are needed to determine the independent effect of HBC.
PATIENTS AND METHODS: This single-center, open-label, randomized exploratory study included 40 infants with superficial IHs, who were assigned to an HBC group or a control group at a 1:1 ratio. Both groups received PDL. The HBC group received immediate post-laser topical application of the optimized HBC-carteolol mixture, whereas the control group received conventional topical carteolol wet-compress therapy after PDL. The predefined efficacy assessment was performed at the 6-month visit, while clinical follow-up continued for 6 to 12 months as routine clinical follow-up. The primary endpoint was the number of PDL treatment sessions completed during the 6-month treatment period. Secondary outcomes included 6-month Hemangioma Activity Score (HAS), change in HAS from baseline to 6 months, and treatment-related complications.
RESULTS: At the predefined 6-month assessment, the HBC group required fewer treatment sessions than the control group during the 6-month treatment period (3.5 ± 0.6 vs 4.7 ± 0.7, P < 0.001). The 6-month HAS was numerically lower in the HBC group than in the control group, but the difference was not statistically significant (0.3 ± 0.4 vs 0.4 ± 0.4, P = 0.272). The HAS change score also did not differ significantly between groups (4.6 ± 0.5 vs 4.5 ± 0.5, P = 0.440). The aggregate treatment-related local complication rate was lower in the HBC group than in the control group (5.0% vs 35.0%, P = 0.048).
CONCLUSION: In this single-center exploratory randomized study, the HBC-carteolol-PDL regimen was associated with fewer treatment sessions and complications than conventional carteolol wet-compress therapy combined with PDL. Further component-controlled studies are needed to determine the independent effect of HBC.